Molecular analysis of glioblastoma: Pathway profiling and its implications for patient therapy

Cancer Biology and Therapy

Volumn 2, Issue 3, 2003, Pages 242-247

  Mischel, Paul S ^a   Nelson, Stanley F ^a   Cloughesy, Timothy F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Gene expressionprofiling; Glioblastoma; Microarray; Molecular analysis; Phosphatidylinositol 3 kinase (PI3K); PTEN; Signal transduction

Indexed keywords

ANIMAL; BRAIN TUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; GLIOBLASTOMA; HUMAN; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BRAIN NEOPLASMS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; SIGNAL TRANSDUCTION;

EID: 0642306004     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.2.3.369     Document Type: Review

References (41)

1. Gurney JG, Kadan-Lottick N. Brain and other central nervous system tumors: rates, trends, and epidemiology. Curr Opin Oncol 2001; 13:160-6 (Pubitemid 32433971)
2. Mischel PS, Cloughesy, T.F. Targeted molecular therapy of glioblastoma. Brain Pathology 2003; 13:52-61.
3. Holland EC. Gliomagenesis: genetic alterations and mouse models. Nat Rev Genet 2001; 2(:120-9.
4. Kleihues P, Ohgaki H. Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro-oncol 1999; 1:44-51.
5. von Deimling A, von Ammon K, Schoenfeld D, Wiestler OD, Seizinger BR, Louis DN. Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 1993; 3:19-26. (Pubitemid 23046372)
6. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002; 61:215-25; discussion 226-9. (Pubitemid 34212596)
7. Okada Y, Hurwitz EE, Esposito JM, Brower MA, Nutt CL, Louis DN. Selection pressures of TP53 mutation and microenvironmental location influence epidermal growth factor receptor gene amplification in human glioblastomas. Cancer Res 2003; 63:413-6. (Pubitemid 36152501)
8. Sawyers CL. Rational therapeutic intervention in cancer: kinases as drug targets. Curr Opin Genet Dev 2002; 12:111-5. (Pubitemid 34094999)
9. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 2001; 98:10314-9. (Pubitemid 32803017)
10. Joensuu H. [Tyrosine kinase inhibitor as a targeted therapy for GIST tumors]. Duodecim 2002; 118:2305-12.
11. Druker BJ. Perspectives on the development of a molecularly targeted agent. Cancer Cell 2002; 1:31-6. (Pubitemid 41039173)
12. Sawyers CL. Imatinib GIST keeps finding new indications: successful treatment of dermatofibrosarcoma protuberans by targeted inhibition of the platelet- derived growth factor receptor. J Clin Oncol 2002; 20:3568-9. (Pubitemid 34983211)
13. Betensky RA, Louis DN, Cairncross JG. Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol 2002; 20:2495-9. (Pubitemid 34525735)
14. Staudt LM. Molecular diagnosis of the hematologic cancers. N Engl J Med 2003; 348:1777-85. (Pubitemid 36514709)
15. Ljubimova JY, Lakhter AJ, Loksh A, Yong WH, Riedinger MS, Miner JH, et al. Overexpression of alpha4 chain-containing laminins in human glial tumors identified by gene microarray analysis. Cancer Res 2001; 61:5601-10. (Pubitemid 32694948)
16. Rickman DS, Bobek MP, Misek DE, Kuick R, Blaivas M, Kurnit DM, et al. Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer Res 2001; 61:6885-91. (Pubitemid 32896514)
17. Fuller GN, Hess KR, Rhee CH, Yung WK, Sawaya RA, Bruner JM, et al. Molecular classification of human diffuse gliomas by multidimensional scaling analysis of gene expression profiles parallels morphology-based classification, correlates with survival, and reveals clinically-relevant novel glioma subsets. Brain Pathol 2002; 12:108-16. (Pubitemid 33131367)
18. Shai R, Shi T, Kremen TJ, Horvath S, Liau LM, Cloughesy TF, et al. Gene Expression Profiling Identifies Molecular Subtypes of Gliomas. Oncogene 2003; In Press.
19. Kim S, Dougherty ER, Shmulevich L, Hess KR, Hamilton SR, Trent JM, et al. Identification of combination gene sets for glioma classification. Mol Cancer Ther 2002; 1:1229-36.
20. Fuller GN, Rhee CH, Hess KR, Caskey LS, Wang R, Bruner JM, et al. Reactivation of insulin-like growth factor binding protein 2 expression in glioblastoma multiforme: a revelation by parallel gene expression profiling. Cancer Res 1999; 59:4228-32. (Pubitemid 29418733)
21. Alizadeh AA, Ross DT, Perou CM, van de Rijn M. Towards a novel classification of human malignancies based on gene expression patterns. J Pathol 2001;195:41-52. (Pubitemid 32899044)
22. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999; 286:531-7.
23. MacDonald TJ, Brown KM, LaFleur B, Peterson K, Lawlor C, Chen Y, et al. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 2001; 29:143-52. (Pubitemid 32952650)
24. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-52.
25. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 2002; 415:436-42. (Pubitemid 34100955)
26. Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002; 8:68-74. (Pubitemid 34101731)
27. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98:10869-74. (Pubitemid 32878711)
28. Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996; 6:217-23; discussion 23-4.
29. Mischel PS, Shai R, Shi T, Horvath S, Lu KV, Choe G, et al. Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene 2003; 22:2361-73. (Pubitemid 36566791)
30. Louis DN, Pomeroy, S.L., Golub, T.R., Nutt, C.L. EGFR Gene Amplification and TP53 Mutation Gene Expression Profiles in Glioblastomas. Journal of Neuropathology and Experimental Neurology 2003; 62:Abstract 16.
31. Vogt PK. PI 3-kinase, mTOR, protein synthesis and cancer. Trends Mol Med 2001; 7:482-4. (Pubitemid 33021671)
32. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2:489-501. (Pubitemid 37328931)
33. Feldkamp MM, Lau, N., Guha, A. Signal transduction pathways and their relevance in human astrocytomas. Journal of Neurooncology 1997; 35:223-248. (Pubitemid 27511128)
34. Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, Fuller GN. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet 2000; 25:55-7. (Pubitemid 30257036)
35. Uhrbom L, Dai C, Celestino JC, Rosenblum MK, Fuller GN, Holland EC. Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt. Cancer Res 2002; 62:5551-8.
36. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002; 298:1911-2.
37. Ermoian RP, Furniss CS, Lamborn KR, Basila D, Berger MS, Gottschalk AR, et al. Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival. Clin Cancer Res 2002; 8:1100-6. (Pubitemid 34517646)
38. Frederick L, Wang XY, Eley G, James CD. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 2000; 60:1383-7. (Pubitemid 30152011)
39. Rao RD, Uhm JH, Krishnan S, James CD. Genetic and signaling pathway alterations in glioblastoma: relevance to novel targeted therapies. Front Biosci 2003; 8:E270-80.
40. Blume-Jensen P, Hunter, T. Oncogenic kinase signaling. Nature 2001;411(6835):355-365.
41. Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie A, et al. Analysis of the Phosphatidyl 3'-Kinase Signaling Pathway in Glioblastoma Patients in Vivo. Cancer Research 2003; 63:In Press.